Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital downgrades Redrow to 'sector perform'

(Sharecast News) - RBC Capital Markets downgraded Redrow on Thursday to 'sector perform' from 'outperform' following a period of outperformance and the fact the share price is now linked to that of Barratt Developments. The bank, which left its price target unchanged at 750p, said that when Barratt made its play for Redrow at 1.23x P/B it did not believe the offer reflected the true value of Redrow's business.

"At the time we noted that for more than 70% of its listed life Redrow had traded at a higher valuation than the offer made by Barratt," it said.

"Six weeks on and no other bidder has thrown their hat in the ring. It seems to us therefore that Redrow's share price is, for now, linked to that of Barratt's."

RBC pointed out that Barratt's shares have underperformed the sector since the announcement of the proposed takeover.

"This surprises us as we view Barratt's plan to buy Redrow as a very good one and the price more attractive to Barratt's shareholders than Redrow's," it said. "Barratt offers a liquid way to play the UK housing market, but so do Persimmon and Taylor Wimpey, but without the distortion/disturbance of a major acquisition."

RBC said the deal is likely to complete.

"Whilst our analysis and comparison of Barratt's and Redrow's competitive positioning...is not as detailed as that being completed by the Competition and Markets Authority, we do not see any significant reasons for the transaction to be prevented, there is limited overlap of sites, and therefore the impact on consumer choice in local housing markets will not be material in our view."

The CMA announced last week that it was taking an initial look into Barratt's £2.52bn takeover of Redrow.

The regulator said it was seeking initial views on how the deal could impact competition in the UK. Its invitation to comment closes on April 2 after which it will decide whether to launch a full investigation.

Share this article

Related Sharecast Articles

AstraZeneca makes progress with two breast cancer treatments
(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.
Insurer Beazley keeps guidance after solid Q1 premiums growth
(Sharecast News) - Insurance group Beazley said that first-quarter results were in line with guidance with insurance written premiums (IWP) growing at high single digits.
Blackstone ups bid for Hipgnosis with $1.57bn offer
(Sharecast News) - Music rights owner Hipgnosis said it it agreed terms on a £1.2bn takeover by private equity investor Blackstone, in the latest tit-for-tat battle with rival Concord.
Aukett Swanke flags delays to some contracts
(Sharecast News) - Smart buildings, architectural and design services specialist Aukett Swanke said in an update on Friday that, as outlined in its recent financial statements, it maintained a robust pipeline of interest, although a number of projects had been pushed back.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.